TIL Cell Therapy in Melanoma

Please note: This animation is currently being updated to reflect the February 2024 FDA approval of this therapy. Please continue to explore the website, https://www.YouAndMelanoma.com and check back for this updated animation soon.

This video is from the Animated Patient's Guide to Melanoma https://www.YouAndMelanoma.com, developed by the Melanoma Research Foundation (MRF) and Mechanisms in Medicine Inc.
The mission of the Melanoma Research Foundation is to eradicate melanoma by accelerating medical RESEARCH while EDUCATING to and ADVOCATING for the melanoma community. To learn more about the MRF visit https://melanoma.org.

Connect with the MRF online:
► Facebook:   / melanoma.research.foundation  
► Twitter:   / curemelanoma  
► Instagram:   / curemelanoma  
► YouTube:    / curemelanoma  
► LinkedIn:   / melanoma-research-foundation  
------------------------------------------------------------------------------------------------
Video description:
This animation provides an overview of Tumor Infiltrating Lymphocyte (TIL) Cell Therapy for melanoma. TIL Cell Therapy is a new type of immunotherapy that utilizes TILs to attack cancer cells. On Feb 16th 2024, the FDA approved AMTAGVI, the first cellular therapy indicated for the treatment of adult patients with cutaneous melanoma that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic). AMTAGVI is a tumor-derived autologous T cell immunotherapy composed of a patient's own T cells, a type of cell that helps the immune system fight cancer. Watch to learn how TIL Cell Therapy is prepared in the lab, how the infusion works, its effectiveness, possible side effects, and its current use in melanoma clinical trials. You may want to ask your doctor if TIL Cell Therapy could be an option for you.